Quality assurance of the EORTC radiotherapy trial 22931 for head and neck carcinomas: the dummy run

Détails

ID Serval
serval:BIB_E687B577E11F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Quality assurance of the EORTC radiotherapy trial 22931 for head and neck carcinomas: the dummy run
Périodique
Radiotherapy and Oncology
Auteur⸱e⸱s
Valley  J. F., Bernier  J., Tercier  P. A., Fogliata-Cozzi  A., Rosset  A., Garavaglia  G., Mirimanoff  R. O.
ISSN
0167-8140 (Print)
Statut éditorial
Publié
Date de publication
04/1998
Volume
47
Numéro
1
Pages
37-44
Notes
Clinical Trial
Comparative Study
Journal Article
Multicenter Study --- Old month value: Apr
Résumé
PURPOSE: A dummy run was organized to test the compliance of participating centres with the guidelines of EORTC protocol 22931, which compares high dose radiotherapy with concomitant radiochemotherapy in a postoperative setting for patients presenting with locally advanced head and neck carcinomas. METHODS: In a first step the participants (seven centres, six replies) were asked to define the planning target volume (PTV) in a given patient on the basis of clinical, surgical and radiological (CT-images) data-sets and according to the protocol guidelines. In a second phase a series of CT-reconstructed slices with on- and off-axis PTV outlines were sent to 11 centres (10 replies), which were asked to plan a treatment following the recommendations made in the frame of the trial. RESULTS: The first step of this dummy run emphasized wide intercentre variations in PTV extensions. This fact raises the question of the reproducibility when pooling patients in multicentric trials. The second step indicated a large variability in the field arrangements which was left to the discretion of the investigators. Only three out of 10 of the institutions followed the ICRU 50 recommendations for dose reporting. Moreover, protocol requirements were not met for dose distribution homogeneity in any centre. CONCLUSIONS: In order to reduce intercentre treatment heterogeneities, several actions have been taken by the EORTC Radiotherapy Group, e.g. amendments have been brought to protocol 22931 regarding a better definition of clinical and planning target volumes. Furthermore, a stricter application of the ICRU 50 recommendations for dose reporting has been sought.
Mots-clé
Carcinoma, Squamous Cell/drug therapy/*radiotherapy/surgery Cisplatin/therapeutic use Head and Neck Neoplasms/drug therapy/*radiotherapy/surgery Humans Neoplasm Recurrence, Local Phantoms, Imaging *Quality Assurance, Health Care Radiation Dosage Radiation-Sensitizing Agents/therapeutic use Radiotherapy/*standards Radiotherapy Dosage Radiotherapy Planning, Computer-Assisted/*standards Radiotherapy, Adjuvant Reproducibility of Results
Pubmed
Web of science
Création de la notice
24/01/2008 18:12
Dernière modification de la notice
20/08/2019 17:09
Données d'usage